True Ventures
True Ventures, established in 2005, is a prominent venture capital firm based in Palo Alto, California, with an additional office in San Francisco. The firm specializes in early-stage technology investments, focusing on seed and Series A financing. True Ventures invests in a broad range of sectors, including commerce, consumer, hardware, health, and infrastructure technologies, as well as emerging markets such as e-commerce, mobile, and software services. The firm typically invests between $0.25 million and $3 million per round, aiming for a stake of approximately 20%. With over $3.8 billion under management and a team of over 40 professionals, True Ventures has supported more than 350 companies, creating over 85,000 jobs worldwide. The firm was recognized as Venture Firm of the Year by the National Venture Capital Association in 2018.
Top Stages
Past deals in Chemical
Enveda Biosciences
Series C in 2024
Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.
Enveda Biosciences
Series B in 2024
Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.
Enveda Biosciences
Series B in 2023
Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.
Enveda Biosciences
Series B in 2022
Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.
Enveda Biosciences
Series A in 2021
Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.
Enveda Biosciences
Seed Round in 2020
Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.